Press Releases

 
Press Releases
  Date Title and Summary View
Jun 14, 2017
FREMONT, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, today announced that it has approved inducement option grants to two new empl...
Jun 12, 2017
FREMONT, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Inc. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, presented additional data from its pivotal Phase 2/3 ZOTRIP study eval...
Jun 1, 2017
Late-Breaking Oral and Oral Presentations to feature M207 Acute Migraine Therapy Zotrip Pivotal Trial Data Selected by Headache Society and Drug Delivery Meetings FREMONT, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a specialty ...
May 9, 2017
Pivotal trial of M207 meets co-primary endpoints to establish fast and durable pain relief$29.3 million follow-on offering of common stock provides funding for initiating required safety study and meeting pre-commercialization CMC/ manufacturing criteriaZosano names John P. Walker Interim CEO...
May 8, 2017
FREMONT, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced that it will host a conference call and webcast to be held on Tuesday, May 9, 2017 ...
Mar 22, 2017
FREMONT, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company's proprietary transdermal delivery system, today announced the closing of the previously announced public offering of ...
Mar 17, 2017
FREMONT, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company's proprietary transdermal delivery system, today announced the pricing of an underwritten public offering o...
Mar 1, 2017
FREMONT, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the fourth quarter and year ended December 3...
Feb 13, 2017
41.5% of patients experienced freedom from pain at 2 hours vs. 14.3% for placebo (p 68.3% of patients experienced freedom from most bothersome symptom at 2 hours vs. 42.9% for placebo (p 26.8% of patients experienced freedom from pain at 1 hour vs. 10.4% ...
Jan 23, 2017
FREMONT, Calif., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company's proprietary transdermal delivery system, today announced that it has approved an inducement grant of options to purchase 35,000 shares of the Company's ...
Page:
1
... NextLast
= add release to Briefcase